Skip to main content

Tags

Latest news

Vironova in the ​finals of the Third China Innovation & Entrepreneurship International Competition in Shenzhen

Vironova in the ​finals of the Third China Innovation & Entrepreneurship International Competition in Shenzhen

Press releases   •   Apr 01, 2019 11:00 CEST

Vironova won the 'Swedish Overseas Division Competition' on March 26th in the 'Third China Innovation & Entrepreneurship International Competition 2019'. Competitions were held in nine cities; Stockholm, London, Berlin, Sydney, Tokyo, Tel Aviv, Silicon Valley, Boston and Toronto. On April 10-12, Vironova will participate in the finals in Shenzhen, China.

Meet Vironova at Bioprocessing Summit Europe 2019

Meet Vironova at Bioprocessing Summit Europe 2019

Press releases   •   Mar 05, 2019 11:00 CET

​Meet Vironova at Bioprocessing Summit Europe 2019 on March 19-21 in Lisbon, Portugal. Vironova’s Marketing Director Nina Forsberg will host and moderate a Round table session on the 19th of March at 16:45 on the topics and needs for analytical methods in gene therapy vector characterization.

MiniTEM™ for quality analysis of phage preparations - poster presentation at the Phage Future Congress 2019

MiniTEM™ for quality analysis of phage preparations - poster presentation at the Phage Future Congress 2019

Press releases   •   Jan 21, 2019 10:30 CET

At the Phage Futures Congress in Washington D.C. experts from regulatory bodies, pharmaceutical companies and government institutions will discuss how to actively progress clinical science and viable phage application routes to market. Vironova represenatives will have a poster presentation to show the potential of MiniTEM™, our desktop low-voltage (25 keV) transmission electron microscope.

Artificial Intelligence, Leadership and Lifelong Learning

Artificial Intelligence, Leadership and Lifelong Learning

Press releases   •   Dec 04, 2018 08:00 CET

​Vironova COO Maria Homman was recently involved in staging a seminar and debate at IVA (The Royal Swedish Academy of Engineering Sciences) as part of the IFG Leadership Development program. Based on current and fascinating subjects of artificial intelligence, leadership and lifelong learning, the subjects for the day was 'AI the new leader in a digitized world?'.

Successful presence at cell and gene therapy meet

Successful presence at cell and gene therapy meet

Press releases   •   Oct 22, 2018 09:00 CEST

​Vironova attended the 26th annual meeting of the European Society of Gene and Cell Therapy (ESGCT) in Lausanne, Switzerland. The congress highlighted the latest research, techniques and developments in this field of gene and cell therapy. Vironova participated in the poster presentations, presenting their latest work on the characterization of AAV gene therapy viral vectors.

Great interest in joint seminar between Vironova Biosafety and AsahiKASEI on virus safety and filtration

Great interest in joint seminar between Vironova Biosafety and AsahiKASEI on virus safety and filtration

Press releases   •   Sep 11, 2018 09:00 CEST

Together with AsahiKASEI bioprocess Vironova is hosting a joint seminar entitled “Virus safety and virus filtration of biopharmaceuticals.” The seminar will cover key considerations in validation of virus reduction. Applications using nanofiltration with robust virus removal will be discussed along with commonly used virus reduction steps.

Vironova in panel discussion on cell and gene therapy (Boston)

Vironova in panel discussion on cell and gene therapy (Boston)

Press releases   •   Sep 05, 2018 08:00 CEST

Vironova is participating in a panel discussion at the Cell and Gene Therapy Bioprocessing and Commercialization conference in Boston, represented by Nina Forsberg, Marketing Director. The session is based on a new e-book ”Key Consideration in Gene Therapy Manufacturing for Commercialization”.

Vironova scientists continue to influence the field – new standard approved

Vironova scientists continue to influence the field – new standard approved

Press releases   •   May 11, 2018 13:00 CEST

Vironova, being identified as leading experts in the characterization of liposomes, was invited by the FDA to participate in developing a standard for electron microscopy of liposomes. The standard is produced by the ASTM International (originally the American Society for Testing and Materials) and the standards are used all over the world, with 140 countries participating in their development.

Best practices from Vironova Biosafety in new publication

Best practices from Vironova Biosafety in new publication

Press releases   •   May 09, 2018 09:30 CEST

An article entitled “Putting viral clearance capabilities to the test” was published on Biopharm International with contributions by Gustav Gilljam, client project manager at Vironova Biosafety. He describes key elements to planning a virus clearance validation and the article as a whole, with contributions from several experts, gives a thorough overview of the scope and challenges of this work.

BPI Eu Summit Amsterdam – Vironova gains increasing attention from growing gene therapy segment

BPI Eu Summit Amsterdam – Vironova gains increasing attention from growing gene therapy segment

Press releases   •   Apr 26, 2018 14:00 CEST

Vironova attended BPI Amsterdam with a booth and presentation. It was evident that the cell and gene therapy industry has developed rapidly the last year with the commitment of Big Pharma to cell and gene therapies. Viral vectors for therapeutic and vaccine applications are expected to become future high value products.

New article on viral quality assessment published

New article on viral quality assessment published

Press releases   •   Feb 01, 2018 10:15 CET

​Vironova has published an extensive article on The Cell Culture Dish. It covers the use of MiniTEM for assessing viral article quality and features Mathieu Colomb-Delsuc, PhD, our senior scientist in Electron microscopy. Mathieu focusses on analysis of drug carriers such as liposomal formulations and AAV particles using CryoTEM.

MiniTEM contributes to the success of our customers

MiniTEM contributes to the success of our customers

Press releases   •   Dec 08, 2017 09:00 CET

​The event at Cell & Gene Therapy in Amsterdam this week was a successful showcase for MiniTEM. Apart from our own activities at our booth and a presentation in the main program we also received an excellent testimonial

Vironova’s CEO, Mohammed Homman, has been elected onto IVA’s Business Executives Council (Näringslivsrådet)

Vironova’s CEO, Mohammed Homman, has been elected onto IVA’s Business Executives Council (Näringslivsrådet)

Press releases   •   Dec 04, 2017 15:00 CET

​The Royal Swedish Academy of Engineering Sciences (Kungl. Ingenjörsvetenskapsakademien, IVA) Business Executives Council met on November 29 for their annual meeting at which we are proud to announce that Vironova’s CEO, Mohammed Homman was elected onto the Board.

Vironova awarded funding to advance expertise in artificial intelligence and machine learning for future healthcare

Vironova awarded funding to advance expertise in artificial intelligence and machine learning for future healthcare

Press releases   •   Nov 21, 2017 11:16 CET

Vironova has been awarded funding for a two-year project on Artificial Intelligence (AI) and Machine Learning for future healthcare applications. The project is part of a joint initiative by VINNOVA, Formas and the Swedish Energy Agency, in collaboration with Huddinge University Hospital and Uppsala University Hospital, adding to our already front-line expertise in applying AI to image analysis.

Vironova is part of major effort to advance Sweden’s position in biological drugs

Vironova is part of major effort to advance Sweden’s position in biological drugs

Press releases   •   Jul 10, 2017 08:43 CEST

Vironova’s expertise makes us perfectly placed to participate in a major effort for development of biological drugs - recently presented by Vinnova and the Swedish Research Council. Biological structures are complex to work with; the manufacturing process must ensure product quality and needs to be monitored with many analytical methods such as Vironova’s MiniTEM system.

Vironova AB and AstraZeneca are partners in FoRmulaEx, a new Industrial Research Centre receiving 75Million SEK from SSF to work on key development bottlenecks for powerful new medicines

Vironova AB and AstraZeneca are partners in FoRmulaEx, a new Industrial Research Centre receiving 75Million SEK from SSF to work on key development bottlenecks for powerful new medicines

Press releases   •   Jul 06, 2017 11:10 CEST

As previously reported on www.vironova.com, Vironova AB, AstraZeneca, Camurus AB and key research groups headed up by Chalmers University of technology, have teamed up in the FoRmulaEx centre, a new multi-disciplinary Industrial Research Centre that has recently received funding of 75M SEK from the Swedish foundation for Strategic Research (SSF). The focus is on complex, oligonucleotide drugs.

Vironova awarded a key US patent for further automation of transmission electron microscopy

Vironova awarded a key US patent for further automation of transmission electron microscopy

Press releases   •   Apr 21, 2017 09:59 CEST

Vironova has recently been granted a US patent with the title " A method for automatic correction of astigmatism.” The method removes a tedious manual step that requires considerable operator skill. It can be applied to any electron microscope, allowing for automated correction of the electron beam and ultimately enabling fully automated image acquisition.

Record turnover for NOW Electronics in its first year as a Vironova-owned company

Record turnover for NOW Electronics in its first year as a Vironova-owned company

Press releases   •   Mar 16, 2017 10:30 CET

NOW Electronics report record turnover of 25,9 MSEK in the first year as a Vironova-owned company. In 2016 Mikael Wik was appointed as CEO. The two founders and leaders since 1985 continue to be active in sales and business development. NOW continues to grow, with a focus on new recruitments, long-term projects and the life science sector. The core business of in-house consulting will continue.

Vironova AB is collaborating partner in Big Data and Computational Science project that received 29 M SEK in funding from the Swedish foundation for Strategic Research.

Vironova AB is collaborating partner in Big Data and Computational Science project that received 29 M SEK in funding from the Swedish foundation for Strategic Research.

Press releases   •   Feb 28, 2017 11:24 CET

Vironova AB is once again a proud participant in a cutting-edge research program. The Swedish foundation for Strategic Research (SSF) has announced 29 M SEK in funding for the project entitled “Hierarchical Analysis of Temporal and Spatial Image Data,” led by Uppsala University Professor Carolina Wählby. Other partners in the project are Astra Zeneca and SciLifeLab

Vironova AB signs one-year agreement with the U.S. Food and Drug Administration to beta test proprietary Vironova Analyzing Software (VAS).

Vironova AB signs one-year agreement with the U.S. Food and Drug Administration to beta test proprietary Vironova Analyzing Software (VAS).

Press releases   •   Feb 23, 2017 15:07 CET

Vironova AB has signed an agreement with the U.S. Food and Drug Administration for beta-testing of the Vironova Analyzing Software (VAS). The testing will help accelerate development and improve robustness and user friendliness of VAS, which is used in combination with Cryo-transmission electron microscopy (cryoTEM) to enable semi-automated image analysis of liposomes.